Watch our webinar with Avecho Biotechnology, featuring CEO Dr Paul Gavin. A presentation followed by live Q&A with the audience.

Avecho Biotechnology Limited develops innovative pharmaceutial products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs to create medicines with better therapeutic effect. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) capsule currently undergoing Phase III clinical development for the treatment of insomnia.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.